

PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Alecensa Prior Authorization Policy

- Alecensa® (alectinib capsules – Genentech)

REVIEW DATE: 02/24/2021

OVERVIEW

Alecensa, a tyrosine kinase inhibitor, is indicated for the treatment of patients with **anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC)**, as detected by an FDA-approved test.¹

GUIDELINES

According to the National Comprehensive Cancer Network (NCCN) NSCLC guidelines (version 3.2021 – February 16, 2021), Alecensa is one of the category 1 preferred therapies for ALK+ NSCLC.² Alunbrig™ (brigatinib tablets) and Lorbrena (lorlatinib tablets) are also noted as category 1, preferred therapies, similar to Alecensa. Zykadia™ (ceritinib capsules) is a category 1 recommendation listed under “other recommended” therapies. Xalkori® (crizotinib capsules) is a category 1 recommended option noted under “useful in certain circumstances”. For progression on one of Alecensa, Zykadia, Lorbrena, or Alunbrig as first-line therapy, continuing with the same therapies or other local therapies (surgery, radiation); use of Lorbrena, if not previously given; or other systemic therapy options are recommended.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Alecensa. All approvals are provided for 3 years in duration unless otherwise noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Alecensa is recommended in those who meet the following criteria:

FDA-Approved Indications

1. **Non-Small Cell Lung Cancer (NSCLC).** Approve for 3 years if the patient has *metastatic* anaplastic lymphoma kinase (ALK)-positive NSCLC as detected by an approved test.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Alecensa is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Alecensa[®] capsules [prescribing information]. South San Francisco, CA: Genentech; January 2021.
2. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 3.2021 – February 16, 2021). © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed February 18, 2021.